Please login to the form below
renal cell carcinoma
This page shows the latest renal cell carcinoma news and features for those working in and with pharma, biotech and healthcare.
Daily Brief: Resignation throws Brexit into disarray, Celgene exec joins Orchard board, Scotland rules on kidney cancer drug
EUSA’s Fotivda approved for NHS use in Scotland. Specialist pharma company EUSA Pharma has welcomed the Scottish Medicines Consortium approval of its renal cell carcinoma treatment Fotivda (tivozanib). ... The SMC has approved its use on the NHS as a
Latest news
-
BMS presses go on Nektar combo pivotal trials, despite data debate
The phase I/II PIVOT trial met the criteria needed to advance PD-1 inhibitor Opdivo (nivolumab) and CD122-biased agonist NKTR0214 into pivotal trials in melanoma, renal cell carcinoma and
-
Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?
EUROPE. European approval for Cabometyx in RCC. The European Commission has approved Ipsen and Exelixis’Cabometyx for the first-line treatment of adults with advanced renal cell carcinoma (RCC).
-
Immuno-oncology at ASCO: survival data, combinations and new indications
in small-cell lung cancer, gastric or gastroesophageal junction (G/GEJ) cancer and Merkel cell carcinoma. ... There will also be presentations on the Tecentriq/Avastin combination in advanced renal cell carcinoma (RCC) and first-line hepatocellular
-
Lilly buys Armo for $1.6bn to bolster immuno-oncology pipeline
in pancreatic cancer, as well as earlier-stage trials in other advanced solid tumours including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC).
-
Roche eyes September FDA verdict for triple NSCLC therapy
The FDA has started a six-month review of Roche’s Tecentriq, Avastin and chemotherapy in first-line non-small cell lung cancer, setting up a possible approval by 5 September. ... Roche is pairing Tecentriq and Avastin in multiple cancer indications,
More from news
Approximately 5 fully matching, plus 133 partially matching documents found.
Latest Intelligence
-
Accelerating innovation
Although marketed as the orphan drug Cometriq for thyroid neoplasms, it’s as Cabometyx in renal cell carcinoma (RCC) where the firm views real potential.
-
Charting a course for expansion
Its first US approval came in April for second-line treatment of renal cell carcinoma (RCC), a prevalent and difficult-to-diagnose cancer, with European regulators giving it the green light ... It showed that Cabometyx can decrease the rate of disease
-
Deal Watch March 2016
Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal Cell Carcinoma, Hepatocellular Carcinoma, other indications) and Cometriq (medullary thyroid cancer).
-
Deal Watch December 2015
510. SQZ Biotech (US). Roche. Collaboration, licence. B cell engineering platform to discover oncology targets . ... 405. Aveo (US). EUSA. Collaboration, licence. Pre-registration tivozanib for renal cell carcinoma.
-
Pharma deals during April 2014
Additional GSK products include the VEGFR inhibitor, Votrient (renal cell carcinoma), Tykerb (HER2 metastatic breast cancer), Arzerra (chronic lymphocytic leukaemia) and Promacta (thrombocytopenia). ... This was largely driven by the phase 2 autologous
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
AVEO appoints Nikhil Mehta as its senior VP, regulatory and quality assurance
and oncology that we believe will be invaluable as we plan and advance our US registration strategy for tivozanib as a potential treatment for renal cell carcinoma.”.
-
CytomX appoints Rachel Humphrey chief medical officer
Humphrey also spent time at Bayer where she oversaw the early and late stage clinical development of the renal cell carcinoma treatment Nexavar (sorafenib).
-
Bayer’s former oncology head Robert Rosen joins AP Pharma
During this time, he led the launch of Nexavar (sorafenib), which made more than $1bn last year, for the treatment of renal cell carcinoma and hepatocellular carcinoma.
-
Former Bayer oncology head Robert Rosen joins AP Pharma's board
Former Bayer oncology head Robert Rosen joins AP Pharma's board. While at Bayer Rosen led launch of Nexavar for renal cell carcinoma and hepatocellular carcinoma. ... Rosen was in charge of Bayer's oncology efforts from 2005 to 2011, where he led the
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?
CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma? ... In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients.
-
A stumble, but not a fall – what’s next for Opdivo?
and renal cell carcinoma (kidney cancer). ... Back then, the UK’ s cost-effectiveness watchdog NICE deemed Opdivo too pricey for renal cell carcinoma when taking into account the availability of Pfizer's Inlyta at a markedly lower
More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.
Featured jobs
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
- Business Unit Head, Medical Communications, London
-
Excellent package
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
Subscribe to our email news alerts
- Moving annual total (MAT)
- Brexit rebels win vote on European Medicines Agency alignment
- MaxCyte gets green light for solid tumour cell therapy
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- NHS England to Vertex: come clean on Orkambi offer
- AstraZeneca joins Merck in Brexit stockpiling effort
- Random42 win Creativity International Award for Scientific Animation
- Merck & Co joins big pharma pricing pledge – but sceptics unconvinced
- Aurora partners with PIPHealth and taps into patient panels
- FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics
- Allergan’s abicipar matches AMD blockbuster Lucentis in phase III
- OUTiCO growth in multi-channel creates more job openings
PMHub
Cello Health
Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
